Sign in

    Brian Markison

    Chief Executive Officer (CEO) at Lantheus Holdings Inc
    Board
    Since March 1, 2024
    Age
    64 years
    Education
    Holds a Bachelor of Science degree from Iona College.
    Tenure
    Joined LNTH as a member of the Board of Directors in September 2012, became Chairperson in January 2013, and assumed the CEO role on March 1, 2024.

    Also at Lantheus Holdings Inc

    AM
    Amanda Morgan
    Chief Commercial Officer (CCO)
    DMN
    Daniel M. Niedzwiecki
    Chief Administrative Officer, General Counsel, and Corporate Secretary
    DJP
    Dr. Jean-Claude Provost
    Chief Science Officer (CSO)

    About

    Brian Markison has built an impressive career in the pharmaceutical and healthcare industries over the past 40 years, demonstrating extensive expertise in operational management, marketing, and commercial development. His solid academic foundation, highlighted by earning a Bachelor of Science degree, has been complemented by hands-on leadership roles at prominent organizations in the sector.

    Throughout his career, he has taken on progressively important roles, serving in senior positions at companies such as Bristol-Myers Squibb, King Pharmaceuticals, Fougera Pharmaceuticals, and RVL Pharmaceuticals. His experience ranges from leading product introductions to executing strategic operational initiatives, positioning him as a notable figure in the industry.

    At LNTH, his journey has been marked by significant milestones. Initially joining the Board of Directors in September 2012, he advanced to Chairperson in January 2013 and ultimately assumed the role of Chief Executive Officer on March 1, 2024. His contributions in steering the company’s strategy and overseeing a smooth leadership transition underscore his dedication to fostering growth and innovation within the organization.

    $LNTH Performance Under Brian Markison

    Past Roles

    Organization Role Date Range Details
    Lantheus Holdings (LNTH) Executive Chairman January 23, 2024 – March 1, 2024 Served until his appointment as CEO
    Lantheus Holdings (LNTH) Non-Executive Chairman of the Board September 2012 – January 23, 2024 Joined Board in September 2012 and elevated to Chairman in January 2013
    Fougera Pharmaceuticals Inc. President and Chief Executive Officer N/A Company was sold to Sandoz, the generics division of Novartis AG
    King Pharmaceuticals Chief Operating Officer, President, Chief Executive Officer, and Chairman 2004 – N/A Joined as COO in March 2004, promoted to President and CEO later in 2004, and elected Chairman in 2007
    Bristol-Myers Squibb Various Senior Leadership Positions N/A Held roles including President of Oncology, Virology, and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease, and Dermatology; and Senior Vice President, Operational Excellence and Productivity

    External Roles

    Organization Role Date Range Details
    RVL Pharmaceuticals plc Chief Executive Officer and Director Current
    The College of New Jersey Director Current
    Cosette Pharmaceuticals Board Member Current